HiSilicon: Announcement on Obtaining the "Drug Clinical Trial Approval Notice" for the innovative drug HSK51155 tablets
Securities code: 002653 Securities abbreviation: HiSco Announcement number: 2026-091 HiSco Pharmaceutical Group Co., Ltd.
About obtaining the innovative drug HSK51155 tablets
Announcement of "Drug Clinical Trial Approval Notice"
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete, and that there are no false records, misleading statements or major omissions.
Hisco Pharmaceutical Group Co., Ltd. (hereinafter referred to as the "Company") recently received the "Drug Clinical Trial Approval Notice" issued by the State Food and Drug Administration. The basic information is as follows:
Drug name Dosage form Application matters New drug registration classification
Registration of domestically produced drugs
HSK51155 Tablets Chemicals Class 1
clinical trial
In accordance with the "Drug Administration Law of the People's Republic of China" and relevant regulations, after review, the clinical trial application for HSK51155 tablets accepted in June 2026 met the relevant requirements for drug registration, and it was agreed to carry out clinical trials for this product.
1. Introduction to R&D projects
HSK51155 is an oral small molecule analgesic drug independently developed by the company with independent intellectual property rights, and is intended to be used clinically for pain-related treatment.
In April 2026, the company reached a cooperation agreement with AbbVie Group Holdings Ltd. (hereinafter referred to as "AbbVie") on HSK51155 and other related projects, granting exclusive rights to development, production and commercialization worldwide except for mainland China, Hong Kong Special Administrative Region and Macau Special Administrative Region to AbbVie. The total potential transaction amount exceeds US$700 million.
2. Risk warning
Innovative drug research and development has a long cycle, many links, and high risks, and is easily affected by some uncertain factors. Investors are advised to make prudent decisions and pay attention to preventing investment risks. The company will promptly fulfill its information disclosure obligations based on the subsequent progress of the project.
Announcement is hereby made.
Board of Directors of HiSco Pharmaceutical Group Co., Ltd.
August 19, 2026